Annual CFO
-$124.20 M
+$145.99 M+54.03%
31 December 2023
Summary:
Intra-Cellular Therapies annual cash flow from operations is currently -$124.20 million, with the most recent change of +$145.99 million (+54.03%) on 31 December 2023. During the last 3 years, it has risen by +$105.87 million (+46.02%). ITCI annual CFO is now -557.04% below its all-time high of -$18.90 million, reached on 31 December 2012.ITCI Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
-$26.52 M
-$27.07 M-4993.91%
30 September 2024
Summary:
Intra-Cellular Therapies quarterly cash flow from operations is currently -$26.52 million, with the most recent change of -$27.07 million (-4993.91%) on 30 September 2024. Over the past year, it has dropped by -$1.25 million (-4.97%). ITCI quarterly CFO is now -4993.91% below its all-time high of $542.00 thousand, reached on 30 June 2024.ITCI Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
-$62.16 M
-$1.25 M-2.06%
30 September 2024
Summary:
Intra-Cellular Therapies TTM cash flow from operations is currently -$62.16 million, with the most recent change of -$1.25 million (-2.06%) on 30 September 2024. Over the past year, it has increased by +$99.17 million (+61.47%). ITCI TTM CFO is now -627778.79% below its all-time high of -$9900.00, reached on 30 June 2013.ITCI TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ITCI Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +54.0% | -5.0% | +61.5% |
| 3 y3 years | +46.0% | +66.5% | +75.6% |
| 5 y5 years | -5.1% | +11.6% | +49.1% |
ITCI Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +54.0% | -4993.9% | +72.0% | -2.1% | +81.2% |
| 5 y | 5 years | -5.1% | +54.0% | -4993.9% | +72.0% | -2.1% | +81.2% |
| alltime | all time | -557.0% | +54.0% | -4993.9% | +72.0% | <-9999.0% | +81.2% |
Intra-Cellular Therapies Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$26.52 M(-4993.9%) | -$62.16 M(+2.1%) |
| June 2024 | - | $542.00 K(-101.6%) | -$60.91 M(-38.0%) |
| Mar 2024 | - | -$34.12 M(+1555.3%) | -$98.25 M(-20.9%) |
| Dec 2023 | -$124.20 M(-54.0%) | -$2.06 M(-91.8%) | -$124.20 M(-23.0%) |
| Sept 2023 | - | -$25.27 M(-31.3%) | -$161.33 M(-14.8%) |
| June 2023 | - | -$36.80 M(-38.7%) | -$189.41 M(-23.4%) |
| Mar 2023 | - | -$60.07 M(+53.3%) | -$247.40 M(-8.4%) |
| Dec 2022 | -$270.19 M(+4.1%) | -$39.19 M(-26.5%) | -$270.19 M(-11.2%) |
| Sept 2022 | - | -$53.35 M(-43.7%) | -$304.18 M(-7.9%) |
| June 2022 | - | -$94.79 M(+14.4%) | -$330.09 M(+12.0%) |
| Mar 2022 | - | -$82.85 M(+13.2%) | -$294.63 M(+13.5%) |
| Dec 2021 | -$259.54 M(+12.8%) | -$73.18 M(-7.7%) | -$259.54 M(+1.9%) |
| Sept 2021 | - | -$79.27 M(+33.6%) | -$254.60 M(+6.6%) |
| June 2021 | - | -$59.33 M(+24.2%) | -$238.91 M(+5.4%) |
| Mar 2021 | - | -$47.77 M(-30.0%) | -$226.61 M(-1.5%) |
| Dec 2020 | -$230.07 M(+79.8%) | -$68.24 M(+7.3%) | -$230.07 M(+16.9%) |
| Sept 2020 | - | -$63.58 M(+35.2%) | -$196.89 M(+20.6%) |
| June 2020 | - | -$47.02 M(-8.2%) | -$163.30 M(+13.7%) |
| Mar 2020 | - | -$51.23 M(+46.1%) | -$143.58 M(+12.2%) |
| Dec 2019 | -$127.98 M(+8.3%) | -$35.06 M(+16.9%) | -$127.98 M(+4.8%) |
| Sept 2019 | - | -$29.99 M(+9.8%) | -$122.09 M(+1.3%) |
| June 2019 | - | -$27.31 M(-23.4%) | -$120.51 M(-5.0%) |
| Mar 2019 | - | -$35.63 M(+22.2%) | -$126.81 M(+7.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2018 | -$118.17 M(+46.8%) | -$29.16 M(+2.6%) | -$118.17 M(+3.8%) |
| Sept 2018 | - | -$28.41 M(-15.5%) | -$113.80 M(+14.0%) |
| June 2018 | - | -$33.61 M(+24.6%) | -$99.80 M(+9.6%) |
| Mar 2018 | - | -$26.98 M(+8.8%) | -$91.08 M(+13.2%) |
| Dec 2017 | -$80.49 M(-11.8%) | -$24.79 M(+72.0%) | -$80.49 M(-4.3%) |
| Sept 2017 | - | -$14.41 M(-42.1%) | -$84.15 M(-15.3%) |
| June 2017 | - | -$24.89 M(+51.8%) | -$99.39 M(+12.9%) |
| Mar 2017 | - | -$16.40 M(-42.4%) | -$88.01 M(-3.6%) |
| Dec 2016 | -$91.26 M(-10.8%) | -$28.45 M(-4.1%) | -$91.26 M(-6.7%) |
| Sept 2016 | - | -$29.66 M(+119.7%) | -$97.86 M(+10.3%) |
| June 2016 | - | -$13.50 M(-31.3%) | -$88.72 M(-16.5%) |
| Mar 2016 | - | -$19.65 M(-43.9%) | -$106.22 M(+3.9%) |
| Dec 2015 | -$102.28 M(+348.5%) | -$35.06 M(+70.9%) | -$102.28 M(+39.3%) |
| Sept 2015 | - | -$20.51 M(-33.8%) | -$73.43 M(+28.1%) |
| June 2015 | - | -$31.00 M(+97.4%) | -$57.34 M(+81.8%) |
| Mar 2015 | - | -$15.71 M(+153.1%) | -$31.53 M(+38.3%) |
| Dec 2014 | -$22.81 M(+1.0%) | -$6.21 M(+40.4%) | -$22.81 M(+37.4%) |
| Sept 2014 | - | -$4.42 M(-14.9%) | -$16.60 M(+36.3%) |
| June 2014 | - | -$5.20 M(-25.6%) | -$12.18 M(+74.2%) |
| Mar 2014 | - | -$6.98 M(>+9900.0%) | -$6.99 M(>+9900.0%) |
| Dec 2013 | -$22.59 M(+19.5%) | - | - |
| June 2013 | - | -$9900.00 | -$9900.00 |
| Dec 2012 | -$18.90 M | - | - |
FAQ
- What is Intra-Cellular Therapies annual cash flow from operations?
- What is the all time high annual CFO for Intra-Cellular Therapies?
- What is Intra-Cellular Therapies annual CFO year-on-year change?
- What is Intra-Cellular Therapies quarterly cash flow from operations?
- What is the all time high quarterly CFO for Intra-Cellular Therapies?
- What is Intra-Cellular Therapies quarterly CFO year-on-year change?
- What is Intra-Cellular Therapies TTM cash flow from operations?
- What is the all time high TTM CFO for Intra-Cellular Therapies?
- What is Intra-Cellular Therapies TTM CFO year-on-year change?
What is Intra-Cellular Therapies annual cash flow from operations?
The current annual CFO of ITCI is -$124.20 M
What is the all time high annual CFO for Intra-Cellular Therapies?
Intra-Cellular Therapies all-time high annual cash flow from operations is -$18.90 M
What is Intra-Cellular Therapies annual CFO year-on-year change?
Over the past year, ITCI annual cash flow from operations has changed by +$145.99 M (+54.03%)
What is Intra-Cellular Therapies quarterly cash flow from operations?
The current quarterly CFO of ITCI is -$26.52 M
What is the all time high quarterly CFO for Intra-Cellular Therapies?
Intra-Cellular Therapies all-time high quarterly cash flow from operations is $542.00 K
What is Intra-Cellular Therapies quarterly CFO year-on-year change?
Over the past year, ITCI quarterly cash flow from operations has changed by -$1.25 M (-4.97%)
What is Intra-Cellular Therapies TTM cash flow from operations?
The current TTM CFO of ITCI is -$62.16 M
What is the all time high TTM CFO for Intra-Cellular Therapies?
Intra-Cellular Therapies all-time high TTM cash flow from operations is -$9900.00
What is Intra-Cellular Therapies TTM CFO year-on-year change?
Over the past year, ITCI TTM cash flow from operations has changed by +$99.17 M (+61.47%)